Drug Discovery/Development
Novozymes Biopharma’s recombinant human albumin helps innovative dry eye therapy move into clinical trials
Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, has announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II development by the FDA.
Most Popular
Study identifies “chink in the armour” of Schmallenberg virusPatients at risk of heart disease set to benefit from clinical trialTransgene announces its invesment in ElsaLys BiotechAuxogyn selected to present at European BioEquity Conference in StockholmNovozymes Biopharma’s recombinant human albumin helps innovative dry eye therapy move into clinical trials
Latest Videos
PrevNext
Open source microscopy – a new era of frame design
Reproducible isolation of high quality RNA
JULABO Temperature Control and Flow Measurement 
Affordable Benchtop NMR Spectrometer | Thermo Scientific™ picoSpin 45 
Device Integration | Thermo Scientific Momentum 3 
How stem cells work and develop
Nanomachines make bionic proteins
Open source microscopy – a new era of frame designReproducible isolation of high quality RNAJULABO Temperature Control and Flow Measurement Affordable Benchtop NMR Spectrometer | Thermo Scientific™ picoSpin 45 Device Integration | Thermo Scientific Momentum 3 How stem cells work and developNanomachines make bionic proteins
Study identifies “chink in the armour” of Schmallenberg virus
A key building block in the Schmallenberg virus could be targeted by anti-viral drugs, according to a new study led from the University of Leeds.
Genomics to reshape endometrial cancer treatment
The most in-depth look yet at endometrial cancer shows that adding genomics-based testing to the standard diagnostic workup could change the recommended course of treatment for some women.
Drug discovery techniques focus on speed and cost reduction
Drug discovery relies on a huge range of techniques, from polymerase chain reaction analysis to clinical trial design. Here we highlight the latest innovations designed to cut costs and increase the speed of new drug discovery
Patients at risk of heart disease set to benefit from clinical trial
Patients suffering from high blood pressure - the single most important risk for death worldwide - could be helped by a UK-wide clinical trial aimed at improving treatments.
Auxogyn selected to present at European BioEquity Conference in Stockholm
BioEquity is the top European event for life science investors showcasing companies on the forefront of innovation.
Transgene announces its invesment in ElsaLys Biotech
The Start-up company will develop therapeutic antibodies against novel targets in the fields of cancer and inflammation.
Drug candidates hold promise for HIV drugs market
Patients to benefit from potential for improved efficacy in less commonly used types of antiretroviral therapies and one-pill-daily combination drugs
Development and licensing deals speed up new drug development
Technology licensing tie-ups and more targeted discovery solutions are driving new drug developments
Queen’s scientists develop ‘magic bullet’ nanomedicine for Acute Lung Injury
Researchers at Queen’s University Belfast have devised a ‘magic bullet’ nanomedicine which could become the first effective treatment for Acute Lung Injury or ALI, a condition affecting 20 per cent of all patients in intensive care.
Novartis drug Ilaris® approved by FDA
Novartis announced that the US Food and Drug Administration (FDA) has approved Ilaris® (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older.
World Lupus Day
Oxford Gene Technology marks World Lupus Day with announcement of novel biomarker panel to support earlier SLE diagnosis
European multidisciplinary conference in thoracic oncology
New data presented at EMCTO showed that first-line therapy with gefitinib (IRESSATM) in Caucasian patients with EGFR mutation-positive advanced NSCLC resulted in an ORR of 70% (95% CI 61-78)
New nanoparticles research
A Wayne State University researcher has successfully tested a technique that can lead to more effective use of nanoparticles as a drug delivery system.
Study finds nearly 5 million asthmatics worldwide could benefit from antifungal therapy
An estimated 4,837,000 asthmatics with allergic bronchopulmonary aspergillosis (ABPA) could benefit substantially from antifungal treatment, say researchers from the University of Toronto and Manchester University.
Study confirms Everolimus can overcome Trastuzumab resistance in IN HER-2 positive early breast cancer
A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.
NanoKTN supports regenerative medicine development
UK regenerative medicine platform (UKRMP) safety hub announced
Pages
Newsbrief
ScientistLive: New post: Innovative medication to shatter blood clots with light http://t.co/8ylN0xIQUL
ScientistLive: New post: Novozymes Biopharma’s recombinant human albumin helps innovative dry eye therapy move into clinical trials http://t.co/QUVadkiyjF
ScientistLive: New post: Patients at risk of heart disease set to benefit from clinical trial http://t.co/O1QFZX6MNy
ScientistLive: New post: Novozymes Biopharma’s recombinant human albumin helps innovative dry eye therapy move into clinical trials http://t.co/QUVadkiyjF
ScientistLive: New post: Patients at risk of heart disease set to benefit from clinical trial http://t.co/O1QFZX6MNy
ITCM is a global manufacturer and leading innovator in customised machinery and systems for pharmaceutical packaging and processing.
© 2013 Setform Limited